Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. 1990

E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
Institute of Biological Science, Federal University of Minas Gerais State, Belo Horizonte-MG, Brazil.

Brazilian army conscripts were vaccinated against American cutaneous leishmaniasis by using nonliving polyvalent promastigote Leish vaccine 5 or Leish vaccine 6 (vaccines with five or six Leishmania stocks) with or without Corynebacterium parvum. No statistically significant differences in lymphocyte stimulation indices were found between vaccinated groups with or without C. parvum, but lymphocyte stimulation indices of all vaccinees were significantly higher (P less than 0.001) than those of the placebo group. A correlation of 90% was found between positive skin test results and positive lymphocyte stimulation indices. Eight major antigens with estimated molecular masses of 13.5, 25, 40, 63, 73, 85, 97, and 160 kilodaltons were recognized by Leish vaccine 5 sera. Our finding also demonstrated the predominance of immunoglobulin M antibody in sera of vaccinated subjects and that a component of Leish vaccine 5, gp63, was immunogenic in humans both at the T-cell level and at the antibody level.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007891 Leishmania A genus of flagellate protozoa comprising several species that are pathogenic for humans. Organisms of this genus have an amastigote and a promastigote stage in their life cycles. As a result of enzymatic studies this single genus has been divided into two subgenera: Leishmania leishmania and Leishmania viannia. Species within the Leishmania leishmania subgenus include: L. aethiopica, L. arabica, L. donovani, L. enrietti, L. gerbilli, L. hertigi, L. infantum, L. major, L. mexicana, and L. tropica. The following species are those that compose the Leishmania viannia subgenus: L. braziliensis, L. guyanensis, L. lainsoni, L. naiffi, and L. shawi. Leishmania (Leishmania),Leishmania (Viannia),Leishmania leishmania,Leishmania viannia,Leishmania leishmanias,Leishmania viannias,Leishmanias,Leishmanias (Leishmania),Leishmanias (Viannia),leishmanias, Leishmania,viannias, Leishmania
D007896 Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL). Leishmania Infection,Infection, Leishmania,Infections, Leishmania,Leishmania Infections,Leishmaniases
D008297 Male Males
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D011425 Propionibacterium acnes A bacteria isolated from normal skin, intestinal contents, wounds, blood, pus, and soft tissue abscesses. It is a common contaminant of clinical specimens, presumably from the skin of patients or attendants. Corynebacterium acnes,Corynebacterium parvum
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
January 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene,
E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
November 1976, Nature,
E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
June 2004, Clinical and experimental immunology,
E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
October 1992, British journal of haematology,
E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
January 2024, The Lancet. Infectious diseases,
E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
January 1993, Revista alergia : organo oficial de la Sociedad Mexicana de Alergia e Inmunlogia,
E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
July 1983, Parasite immunology,
E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
May 2012, Human immunology,
E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
January 1985, Reviews of infectious diseases,
E Nascimento, and W Mayrink, and C A da Costa, and M S Michalick, and M N Melo, and G C Barros, and M Dias, and C M Antunes, and M S Lima, and D C Taboada
June 2022, mBio,
Copied contents to your clipboard!